Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective.

Lee YC, Jivraj N, O'Brien C, Chawla T, Shlomovitz E, Buchanan S, Lau J, Croke J, Allard JP, Dhar P, Laframboise S, Ferguson SE, Dhani N, Butler M, Ng P, Stuart-McEwan T, Savage P, Tinker L, Oza AM, Lheureux S.

Obstet Gynecol Int. 2018 May 17;2018:1867238. doi: 10.1155/2018/1867238. eCollection 2018. Review.

2.

Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer.

Grant RC, Holter S, Borgida A, Dhani NC, Hedley DW, Knox JJ, Akbari MR, Zogopoulos G, Gallinger S.

J Genet Couns. 2018 Feb 13. doi: 10.1007/s10897-018-0212-1. [Epub ahead of print]

PMID:
29441441
3.

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.

O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, Kelsen DP.

Cancer. 2018 Apr 1;124(7):1374-1382. doi: 10.1002/cncr.31218. Epub 2018 Jan 16.

PMID:
29338080
4.

Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial.

Aung KL, Fischer SE, Denroche RE, Jang GH, Dodd A, Creighton S, Southwood B, Liang SB, Chadwick D, Zhang A, O'Kane GM, Albaba H, Moura S, Grant RC, Miller JK, Mbabaali F, Pasternack D, Lungu IM, Bartlett JMS, Ghai S, Lemire M, Holter S, Connor AA, Moffitt RA, Yeh JJ, Timms L, Krzyzanowski PM, Dhani N, Hedley D, Notta F, Wilson JM, Moore MJ, Gallinger S, Knox JJ.

Clin Cancer Res. 2018 Mar 15;24(6):1344-1354. doi: 10.1158/1078-0432.CCR-17-2994. Epub 2017 Dec 29.

PMID:
29288237
5.

Impact of tissue transport on PET hypoxia quantification in pancreatic tumours.

Taylor E, Gottwald J, Yeung I, Keller H, Milosevic M, Dhani NC, Siddiqui I, Hedley DW, Jaffray DA.

EJNMMI Res. 2017 Dec 22;7(1):101. doi: 10.1186/s13550-017-0347-3.

6.

Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.

Lheureux S, Butler MO, Clarke B, Cristea MC, Martin LP, Tonkin K, Fleming GF, Tinker AV, Hirte HW, Tsoref D, Mackay H, Dhani NC, Ghatage P, Weberpals J, Welch S, Pham NA, Motta V, Sotov V, Wang L, Karakasis K, Udagani S, Kamel-Reid S, Streicher HZ, Shaw P, Oza AM.

JAMA Oncol. 2017 Nov 16. doi: 10.1001/jamaoncol.2017.3776. [Epub ahead of print]

PMID:
29145543
7.

Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience.

Chiu JW, Krzyzanowska MK, Serra S, Knox JJ, Dhani NC, Mackay H, Hedley D, Moore M, Liu G, Burkes RL, Brezden-Masley C, Roehrl MH, Craddock KJ, Tsao MS, Zhang T, Yu C, Kamel-Reid S, Siu LL, Bedard PL, Chen EX.

Clin Colorectal Cancer. 2018 Mar;17(1):73-79. doi: 10.1016/j.clcc.2017.10.010. Epub 2017 Oct 23.

PMID:
29128266
8.

Long term responders to palliative chemotherapy for advanced biliary tract cancer.

Doherty MK, McNamara MG, Aneja P, McInerney E, Moignard S, Horgan AM, Jiang H, Panzarella T, Jang R, Dhani N, Hedley D, Knox JJ.

J Gastrointest Oncol. 2017 Apr;8(2):352-360. doi: 10.21037/jgo.2017.03.06.

9.

Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).

Spreafico A, Oza AM, Clarke BA, Mackay HJ, Shaw P, Butler M, Dhani NC, Lheureux S, Wilson MK, Welch S, Zhang T, Yu C, Stockley T, Siu LL, Kamel-Reid S, Bedard PL.

Gynecol Oncol. 2017 Feb;144(2):250-255. doi: 10.1016/j.ygyno.2016.12.002. Epub 2017 Jan 3.

PMID:
28062115
10.

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.

Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, Chen EX, Krzyzanowska MK, Dhani N, Joshua AM, Tsao MS, Serra S, Clarke B, Roehrl MH, Zhang T, Sukhai MA, Califaretti N, Trinkaus M, Shaw P, van der Kwast T, Wang L, Virtanen C, Kim RH, Razak AR, Hansen AR, Yu C, Pugh TJ, Kamel-Reid S, Siu LL, Bedard PL.

Genome Med. 2016 Oct 25;8(1):109.

11.

Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.

Connor AA, Denroche RE, Jang GH, Timms L, Kalimuthu SN, Selander I, McPherson T, Wilson GW, Chan-Seng-Yue MA, Borozan I, Ferretti V, Grant RC, Lungu IM, Costello E, Greenhalf W, Palmer D, Ghaneh P, Neoptolemos JP, Buchler M, Petersen G, Thayer S, Hollingsworth MA, Sherker A, Durocher D, Dhani N, Hedley D, Serra S, Pollett A, Roehrl MHA, Bavi P, Bartlett JMS, Cleary S, Wilson JM, Alexandrov LB, Moore M, Wouters BG, McPherson JD, Notta F, Stein LD, Gallinger S.

JAMA Oncol. 2017 Jun 1;3(6):774-783. doi: 10.1001/jamaoncol.2016.3916.

12.

Regression grading in neoadjuvant treated pancreatic cancer: an interobserver study.

N Kalimuthu S, Serra S, Dhani N, Hafezi-Bakhtiari S, Szentgyorgyi E, Vajpeyi R, Chetty R.

J Clin Pathol. 2017 Mar;70(3):237-243. doi: 10.1136/jclinpath-2016-203947. Epub 2016 Sep 28.

PMID:
27681847
13.

FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.

Chllamma MK, Cook N, Dhani NC, Giby K, Dodd A, Wang L, Hedley DW, Moore MJ, Knox JJ.

Br J Cancer. 2016 Sep 6;115(6):649-54. doi: 10.1038/bjc.2016.222. Epub 2016 Jul 28.

14.

The spectrum of histopathological changes encountered in pancreatectomy specimens after neoadjuvant chemoradiation, including subtle and less-well-recognised changes.

Kalimuthu SN, Serra S, Dhani N, Chetty R.

J Clin Pathol. 2016 Jun;69(6):463-71. doi: 10.1136/jclinpath-2016-203604. Epub 2016 Feb 25. Review.

PMID:
26915370
15.

Measurement of Tumor Hypoxia in Patients with Advanced Pancreatic Cancer Based on 18F-Fluoroazomyin Arabinoside Uptake.

Metran-Nascente C, Yeung I, Vines DC, Metser U, Dhani NC, Green D, Milosevic M, Jaffray D, Hedley DW.

J Nucl Med. 2016 Mar;57(3):361-6. doi: 10.2967/jnumed.115.167650. Epub 2016 Jan 14.

16.

Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole.

Dhani NC, Serra S, Pintilie M, Schwock J, Xu J, Gallinger S, Hill RP, Hedley DW.

Br J Cancer. 2015 Sep 15;113(6):864-71. doi: 10.1038/bjc.2015.284. Epub 2015 Sep 1.

17.

Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.

Holter S, Borgida A, Dodd A, Grant R, Semotiuk K, Hedley D, Dhani N, Narod S, Akbari M, Moore M, Gallinger S.

J Clin Oncol. 2015 Oct 1;33(28):3124-9. doi: 10.1200/JCO.2014.59.7401. Epub 2015 May 4.

PMID:
25940717
18.

The clinical significance of hypoxia in human cancers.

Dhani N, Fyles A, Hedley D, Milosevic M.

Semin Nucl Med. 2015 Mar;45(2):110-21. doi: 10.1053/j.semnuclmed.2014.11.002. Review.

PMID:
25704384
19.

A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.

McNamara MG, Le LW, Horgan AM, Aspinall A, Burak KW, Dhani N, Chen E, Sinaei M, Lo G, Kim TK, Rogalla P, Bathe OF, Knox JJ.

Cancer. 2015 May 15;121(10):1620-7. doi: 10.1002/cncr.29227. Epub 2015 Jan 6.

20.

Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods.

Serrano PE, Cleary SP, Dhani N, Kim PT, Greig PD, Leung K, Moulton CA, Gallinger S, Wei AC.

Ann Surg Oncol. 2015 Apr;22(4):1160-7. doi: 10.1245/s10434-014-4196-2. Epub 2014 Oct 28.

PMID:
25348784
21.

A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer.

Renouf DJ, Tang PA, Hedley D, Chen E, Kamel-Reid S, Tsao MS, Tran-Thanh D, Gill S, Dhani N, Au HJ, Wang L, Moore MJ.

Eur J Cancer. 2014 Jul;50(11):1909-15. doi: 10.1016/j.ejca.2014.04.008. Epub 2014 May 21.

PMID:
24857345
22.

Liver resection after chemotherapy and tumour downsizing in patients with initially unresectable colorectal cancer liver metastases.

Devaud N, Kanji ZS, Dhani N, Grant RC, Shoushtari H, Serrano PE, Nanji S, Greig PD, McGilvray I, Moulton CA, Wei A, Gallinger S, Cleary SP.

HPB (Oxford). 2014 May;16(5):475-80. doi: 10.1111/hpb.12159. Epub 2013 Aug 9.

23.

Targeting tumoral hypoxia: finding opportunity in complexity.

Dhani N, Milosevic M.

Future Oncol. 2012 Sep;8(9):1065-8. doi: 10.2217/fon.12.100. No abstract available.

PMID:
23030480
24.

Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.

Dhani NC, Emmenegger U, Adams L, Jongstra J, Tannock IF, Sridhar SS, Knox JJ, Day JR, Groskopf J, Joshua AM.

BJU Int. 2012 Sep;110(6):840-5. doi: 10.1111/j.1464-410X.2011.10922.x. Epub 2012 Feb 7.

25.

Characterization of the Tumor-Microenvironment in Patient-Derived Cervix Xenografts (OCICx).

Chaudary N, Pintilie M, Schwock J, Dhani N, Clarke B, Milosevic M, Fyles A, Hill RP.

Cancers (Basel). 2012 Aug 29;4(3):821-45. doi: 10.3390/cancers4030821.

26.

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.

da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, Squire J, Parulekar W, Moore MJ, Tsao MS.

Cancer. 2010 Dec 15;116(24):5599-607. doi: 10.1002/cncr.25393. Epub 2010 Sep 7.

27.

Targeting focal adhesion kinase signaling in tumor growth and metastasis.

Schwock J, Dhani N, Hedley DW.

Expert Opin Ther Targets. 2010 Jan;14(1):77-94. doi: 10.1517/14728220903460340. Review.

PMID:
20001212
28.

Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.

Schwock J, Dhani N, Cao MP, Zheng J, Clarkson R, Radulovich N, Navab R, Horn LC, Hedley DW.

Cancer Res. 2009 Jun 1;69(11):4750-9. doi: 10.1158/0008-5472.CAN-09-0454. Epub 2009 May 19.

29.

Alternate endpoints for screening phase II studies.

Dhani N, Tu D, Sargent DJ, Seymour L, Moore MJ.

Clin Cancer Res. 2009 Mar 15;15(6):1873-82. doi: 10.1158/1078-0432.CCR-08-2034. Epub 2009 Mar 10. Review.

30.

Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models.

Pham NA, Magalhaes JM, Do T, Schwock J, Dhani N, Cao PJ, Hill RP, Hedley DW.

Int J Cancer. 2009 Jan 15;124(2):280-6. doi: 10.1002/ijc.23912.

31.

Clinical trials and biomarker development with molecularly targeted agents and radiotherapy.

Dhani N, Siu LL.

Cancer Metastasis Rev. 2008 Sep;27(3):339-49. doi: 10.1007/s10555-008-9140-0. Review.

PMID:
18379730

Supplemental Content

Support Center